Groww Logo
Home>US Stocks>Biogen Inc

Biogen Inc

Healthcare
$200.00
- $2.90 (1.43%) 1D
1D
1W
1M
1Y
3Y
5Y

Performance

Today’s Low
$
    Today’s High
    $
    52W Low
    $
      52W High
      $
      Open PricePrev. CloseVolumeAvg. Volume
      $200.13$202.9062,7241,163,646

      Fundamentals

      Market Cap$29.71B
      P/B Ratio2.6
      P/E Ratio20.5
      Enterprise Value$35.55B
      Div. Yield0.00%
      Book Value76.43
      EPS(TTM)9.79
      ROE13.40%
      Understand Fundamentals

      About the Company

      Biogen, Inc. is a multinational biotechnology company that specialises in the treatment of neurological diseases. It discovers, develops, and delivers therapies to treat maladies like multiple sclerosis, Alzheimer’s disease, and spinal muscular atrop
      Biogen, Inc. is a multinational biotechnology company that specialises in the treatment of neurological diseases. It discovers, develops, and delivers therapies to treat maladies like multiple sclerosis, Alzheimer’s disease, and spinal muscular atrophy. The company was established in 1978 by several prominent biologists, including Walter Gilbert and Phillip Allen Sharp. Gilbert served as its CEO during the start-up phase and went on to accept a Nobel Prize in Chemistry in 1980. Subsequently, Sharp was awarded the Nobel Prize for Physiology or Medicine in 1993. The company is headquartered in Cambridge, Massachusetts, United States. Biogen shares trade on the NASDAQ Stock Exchange under the ticker symbol BIIB. It merged with Idec Pharmaceuticals in a $6.8 billion deal and changed its name to Biogen Idec. With this merger, Biogen Idec became one of the largest biotech companies in the world. However, the company later shortened its name, following shifts in its research areas, and reverted to just Biogen. BIIB stock is a component of several indices, namely the NASDAQ 100, S&P 1500, S&P 500 as well as the S&P 100. In 2013, BIIB purchased all rights to Tysabri, a medication for multiple sclerosis, from its partner Elan Pharmaceuticals in a transaction worth $3.25 billion. Over the years, Biogen has expanded its operations through multiple acquisitions. As of 2020, its latest addition to this list is Nightstar Therapeutics in 2019, with a purchase price of approximately $800 million. BIIB operates internationally in the Americas, Europe, and Asia. New Zealand, Japan, Australia, Italy, Germany, China, Belgium, Poland, and South Korea are some of the countries with its corporate offices. In 2020, Forbes included Biogen in its list of Just Companies as well as World’s Best Employers. BIIB ranked 213th on the list of Fortune 500 and 366th on Forbes’ Global 2000 companies.
      ...Read more
      OrganisationBiogen Inc
      IndustryDrug Manufacturers—General
      HeadQuartersCambridge, MA

      Company Financials

      *All values are in Million $
      No Graph Data To Display
      Quarterly
      Yearly
      See Details

      FAQs on Biogen Inc

      Can I Buy Biogen Inc Shares in India?

      Yes, Biogen Inc shares can be bought in India by opening an international trading account with Groww.

      How to Buy Biogen Inc Shares in India?

      One can easily invest in Biogen Inc shares from India by: Direct Investment - Opening an international trading account with Groww which includes KYC verification in the US. Your account gets activated in a few minutes to a few hours, after which you can start adding funds in USD balance to buy Biogen Inc shares. Indirect Investment - Under this form of investment, you can choose either a Mutual Fund (MF) or an Exchange-Traded Fund (ETF) that invests in global shares and start investing in shares of Biogen Inc.

      What is the Share Price of Biogen Inc?

      The share price of Biogen Inc is in Dollars and if you are investing from India, you can always check the INR valuation before investing. The current Biogen Inc share price is $200.00 as of 17 May ‘22

      What is the Market Cap of Biogen Inc?

      The Biogen Inc market cap is $29.71B as of 17 May ‘22

      What is the PE and PB ratio of Biogen Inc?

      The PE and PB ratio of Biogen Inc is 20.5 and 2.6 as of 17 May ‘22
      ⓒ 2016-2022 Groww. All rights reserved, Built with in India
      MOST POPULAR ON GROWWVERSION - 2.3.8
      STOCK MARKET INDICES:  S&P BSE SENSEX |  S&P BSE 100 |  NIFTY 100 |  NIFTY 50 |  NIFTY MIDCAP 100 |  NIFTY BANK |  NIFTY NEXT 50
      MUTUAL FUNDS COMPANIES:  ICICI PRUDENTIAL |  HDFC |  NIPPON INDIA |  ADITYA BIRLA SUN LIFE |  SBI |  UTI |  FRANKLIN TEMPLETON |  KOTAK MAHINDRA |  IDFC |  DSP |  AXIS |  TATA |  L&T |  SUNDARAM |  PGIM |  INVESCO |  LIC |  JM FINANCIAL |  BARODA PIONEER |  CANARA ROBECO |  HSBC |  IDBI |  INDIABULLS |  MOTILAL OSWAL |  BNP PARIBAS |  MIRAE ASSET |  PRINCIPAL |  BOI AXA |  UNION KBC |  TAURUS |  EDELWEISS |  NAVI |  MAHINDRA |  QUANTUM |  PPFAS |  IIFL |  Quant |  SHRIRAM |  SAHARA |  ITI

      ABOUT GROWW